Literature DB >> 14645002

A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins.

Marek Jasinski1, Panagiotis Pantazopoulos, Russell P Rother, Nico van Rooijen, Wen-Chao Song, Hector Molina, Monica Bessler.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by the increased sensitivity of red blood cells (RBCs) to complement, leading to intravascular hemolysis and hemoglobinuria. PNH is due to the expansion of a cell clone that has acquired a mutation in the PIGA gene. Mice with targeted Piga gene inactivation genetically mimic the human disease and have phosphatidylinositol glycan class A-negative (PIGA-) RBCs with a reduced half-life in circulation. Although PIGA-RBCs are hypersensitive to complement in vitro, their complement sensitivity in vivo is barely detectable. Here we show that the shortened survival of PIGA- RBCs is independent of complement either by using inhibitory C5 antibodies or by transfusion into C5-, C4-, C3-, or factor B-deficient mice. Splenectomy or high-dose cortisone treatment had no effect on the shorter survival of PIGA- RBCs. However, treatment with liposome-encapsulated clodronate, an agent that depletes macrophages in vivo, normalized the half-life of PIGA- RBCs. This indicates that the shortened survival of PIGA- RBCs is due to a novel pathway of PIGA- RBC clearance that is mediated by macrophages, but occurs independently of complement. Future investigations will show whether this novel pathway of PIGA- RBC destruction identified in mice may also operate in patients with PNH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645002     DOI: 10.1182/blood-2003-09-3057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.

Authors:  María Virginia Tribulatti; Juan Mucci; Nico Van Rooijen; María Susana Leguizamón; Oscar Campetella
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 3.  Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.

Authors:  Lucio Luzzatto; Giacomo Gianfaldoni
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

4.  Controlling resistant bacteria with a novel class of β-lactamase inhibitor peptides: from rational design to in vivo analyses.

Authors:  Santi M Mandal; Ludovico Migliolo; Osmar N Silva; Isabel C M Fensterseifer; Celio Faria-Junior; Simoni C Dias; Amit Basak; Tapas K Hazra; Octávio L Franco
Journal:  Sci Rep       Date:  2014-08-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.